Clinical and pathological characteristics, treatment outcome and prognostic factors in adult rhabdomyosarcoma: a monocentric retrospective study.
Adult
prognosis
rhabdomyosarcoma
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
08
2021
accepted:
08
03
2022
entrez:
23
6
2022
pubmed:
24
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Rhabdomyosarcoma (RMS) is rare in adults. Our study is the first in Tunisia to report outcomes of adult RMS. We retrospectively analyzed clinical data of adult RMS patients. We collected data regarding clinical characteristics, treatment outcome and prognostic factors. Survival was assessed using the Kaplan Meier method. Forty-seven patients were included. Median age was 39. Twenty-five patients were young adults (53%). Sex ratio (M/F) was 1.9. RMS was localized in 33 patients (70%) and metastatic in 14 patients (30%). Extremities were the most frequent tumor site (40%) followed by trunk (23%). Median tumor size was 9 cm. Pleomorphic RMS was the major subtype (36%). Twenty seven of 33 patients with localized RMS underwent surgery (82%). Relapse free survival (RFS) was 38%. Young adults had a significantly worse RFS than adults aged ≥40 (p = 0.045). Surgery was associated with a significantly better RFS (p = 0.023). Five year overall survival (OS) was 35% and 27% in localized and metastatic RMS respectively. RMS localized in the extremities had significantly poorer OS (p = 0.041), same as non-operated patients (p = 0.025). OS for metastatic RMS was significantly worse after surgery of the primary tumor (p = 0.002). In multivariate analysis, surgery (HR = 0.108; 95%CI (0.023-0.519); p = 0.005) and non-extremity localization (HR = 0.238; 95%CI (0.075-0.751); p = 0.014) were independent prognostic factors for OS in localized RMS. Adults with RMS have poor 5 year OS. Surgery and non-extremity localization were independent prognostic factors for OS in localized RMS.
Identifiants
pubmed: 35734321
doi: 10.11604/pamj.2022.41.246.31425
pii: PAMJ-41-246
pmc: PMC9187987
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
246Informations de copyright
Copyright: Myriam Saadi et al.
Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Anticancer Res. 2015 Nov;35(11):6213-7
pubmed: 26504053
J Clin Oncol. 2009 Jul 10;27(20):3391-7
pubmed: 19398574
Anticancer Res. 2012 Oct;32(10):4485-97
pubmed: 23060577
Cancer Med. 2013 Aug;2(4):553-63
pubmed: 24156028
Cancer. 2002 Jul 15;95(2):377-88
pubmed: 12124838
Br J Radiol. 2020 Aug;93(1112):20200250
pubmed: 32559113
Med Oncol. 2019 May 18;36(7):59
pubmed: 31104202
Nat Rev Dis Primers. 2019 Jan 7;5(1):1
pubmed: 30617281
J Community Hosp Intern Med Perspect. 2020 Jun 14;10(3):287-289
pubmed: 32850081
Curr Treat Options Oncol. 2015 Jun;16(6):27
pubmed: 25975442
Ann Surg. 2001 Aug;234(2):215-23
pubmed: 11505068
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):58-63
pubmed: 23414767
Cancer. 2001 Feb 15;91(4):794-803
pubmed: 11241248
J Surg Oncol. 2011 Dec;104(7):771-5
pubmed: 21744348
Lancet Oncol. 2017 Mar;18(3):e166-e175
pubmed: 28271871
Surg Oncol. 2019 Jun;29:190-195
pubmed: 31196487
Cancer Metastasis Rev. 2019 Dec;38(4):683-694
pubmed: 31797181
Cancer. 2003 Aug 1;98(3):571-80
pubmed: 12879475
Cancer Med. 2018 Aug;7(8):4023-4035
pubmed: 29956493